Print Page | Close Window


November 18, 2014 - 10:08 a.m.
European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4
Printer Friendly Version 
November 12, 2014 - 5:58 p.m.
Gilead Prices $4 Billion of Senior Unsecured Notes
Printer Friendly Version 
November 11, 2014 - 8:01 a.m.
Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment
Printer Friendly Version 
November 11, 2014 - 8:01 a.m.
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C
Printer Friendly Version 
November 06, 2014 - 8:32 a.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV
Printer Friendly Version 
October 28, 2014 - 4:06 p.m.
Gilead Sciences Announces Third Quarter 2014 Financial Results
Printer Friendly Version 
October 21, 2014 - 5:01 p.m.
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014
Printer Friendly Version 
October 16, 2014 - 1:31 p.m.
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
Printer Friendly Version 
October 10, 2014 - 1:55 p.m.
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
Printer Friendly Version 
September 26, 2014 - 7:19 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults
Printer Friendly Version 
September 24, 2014 - 8:31 a.m.
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies
Printer Friendly Version 
September 24, 2014 - 12:01 a.m.
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection
Printer Friendly Version 
September 19, 2014 - 6:24 a.m.
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Printer Friendly Version 
September 17, 2014 - 6:01 a.m.
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer
Printer Friendly Version 
September 15, 2014 - 6:31 a.m.
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries
Printer Friendly Version 
September 08, 2014 - 8:46 a.m.
First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study
Printer Friendly Version 
September 03, 2014 - 5:02 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences in September
Printer Friendly Version 
July 25, 2014 - 7:25 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Printer Friendly Version 
July 24, 2014 - 12:02 a.m.
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries
Printer Friendly Version 
July 23, 2014 - 4:06 p.m.
Gilead Sciences Announces Second Quarter 2014 Financial Results
Printer Friendly Version 
July 23, 2014 - 11:50 a.m.
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma
Printer Friendly Version 
July 16, 2014 - 5:01 p.m.
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014
Printer Friendly Version 
June 27, 2014 - 3:02 a.m.
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C
Printer Friendly Version 
June 16, 2014 - 5:01 p.m.
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17
Printer Friendly Version 
June 15, 2014 - 8:01 p.m.
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan
Printer Friendly Version 
June 09, 2014 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10
Printer Friendly Version 
June 03, 2014 - 8:31 a.m.
Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia
Printer Friendly Version 
May 20, 2014 - 5:01 p.m.
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults
Printer Friendly Version 
May 19, 2014 - 5:01 p.m.
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20
Printer Friendly Version 
May 13, 2014 - 5:01 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14
Printer Friendly Version 
May 10, 2014 - 1:31 p.m.
Gilead Announces Results from Phase 2 Study Showing Reduction in Atrial Fibrillation Burden with the Investigational Combination of Ranolazine and Low-Dose Dronedarone
Printer Friendly Version 
May 09, 2014 - 4:31 p.m.
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome
Printer Friendly Version 
May 07, 2014 - 5:18 p.m.
Gilead Announces $5 Billion Share Repurchase Program
Printer Friendly Version 
April 22, 2014 - 4:03 p.m.
Gilead Sciences Announces First Quarter 2014 Financial Results
Printer Friendly Version 
April 21, 2014 - 5:04 p.m.
Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA
Printer Friendly Version 
April 15, 2014 - 5:01 p.m.
Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Printer Friendly Version 
April 11, 2014 - 1:03 a.m.
Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
Printer Friendly Version 
April 10, 2014 - 1:04 a.m.
Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C
Printer Friendly Version 
April 10, 2014 - 1:03 a.m.
Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Printer Friendly Version 
April 07, 2014 - 8:31 a.m.
Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection
Printer Friendly Version 
April 02, 2014 - 4:31 p.m.
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan
Printer Friendly Version 
March 28, 2014 - 8:31 a.m.
Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014
Printer Friendly Version 
March 27, 2014 - 4:11 p.m.
European Medicines Agency Validates Gilead’s Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection
Printer Friendly Version 
March 04, 2014 - 6:20 p.m.
Gilead Prices $4 Billion of Senior Unsecured Notes
Printer Friendly Version 
February 28, 2014 - 5:01 p.m.
Gilead Sciences to Present at the 34th Cowen & Co. Healthcare Conference on Monday, March 3
Printer Friendly Version 
February 25, 2014 - 5:01 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2014 Global Healthcare Conference on Wednesday, February 26
Printer Friendly Version 
February 10, 2014 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 10, 2014 - 4:06 p.m.
Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C
Printer Friendly Version 
February 04, 2014 - 4:06 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results
Printer Friendly Version 
January 28, 2014 - 5:01 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014
Printer Friendly Version 
January 27, 2014 - 5:01 p.m.
Gilead Announces Executive Promotions
Printer Friendly Version 
January 17, 2014 - 9:10 a.m.
European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection
Printer Friendly Version 
January 13, 2014 - 8:31 a.m.
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma
Printer Friendly Version 
January 10, 2014 - 5:01 p.m.
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13
Printer Friendly Version 
January 06, 2014 - 4:32 p.m.
Gilead Sciences’ Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire
Printer Friendly Version